ENHERTU Followed by THP Approved in China for the Neoadjuvant Treatment of HER2+ve Breast Cancer
“As the first approval of ENHERTU globally for the neoadjuvant treatment of HER2 positive early-stage breast cancer and the first HER2 directed antibody drug conjugate approved in China in this setting, ENHERTU followed by THP offers patients in China a new treatment option with the opportunity to reach a pathologic complete response and the potential for improved long-term outcomes,” said Michio Hayashi, China President, Daiichi Sankyo. “This third approval of ENHERTU in the last three months and seventh approval in three years reinforces the rapid progress we are making in bringing ENHERTU to more patients in China, where there is a high incidence of breast cancer and a continued need for new treatment approaches.
Share:
More News
“The positive outcome of our pre-IND interactions with the FDA reinforces the development pathway for MaaT034 and supports its continued advancement toward the clinic. It also represents an important step in MaaT Pharma’s expansion into immuno-oncology, highlighting the broader potential of our first in class co-cultivated microbiome donor-independent platform across
“Patients with metastatic RAS G12D non-squamous NSCLC, occurring in approximately 4% of cases, represent an underserved population, with no approved targeted treatment options. Initial clinical data evaluating zoldonrasib in combination with standard of care pembrolizumab and platinum doublet chemotherapy in patients with previously untreated metastatic RAS G12D non-squamous NSCLC showed
“At Georgiamune, we are focused on uncovering novel mechanisms that control immune-cell function and translating that biology into first-in-class medicines across autoimmune disease and oncology,” said Samir N. Khleif, M.D., Founder and Chief Executive Officer of Georgiamune. “GIM-621 is one of multiple programs to emerge from that work, alongside three
“Our team’s outstanding execution has enabled us to rapidly advance three programs into the clinic in 2026 and make significant progress in developing next-generation IO, ADC and combination therapies. Together with our partner, Kelun-Biotech, we have achieved seven IND clearances to date, and by mid-2027, we expect more than 2,000